XML 26 R7.htm IDEA: XBRL DOCUMENT

Business Overview	12 Months Ended
Business Overview	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Overview	Business Overview Synergy Pharmaceuticals Inc. ("the Company" or "Synergy") is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The Company has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Synergy discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform that includes one commercial product, TRULANCE, and a second lead product candidate, dolcanatide. TRULANCE is now approved in the United States for the treatment of adults with chronic idiopathic constipation. Synergy has also completed two Phase 3 clinical trials of TRULANCE for the treatment of adults with irritable bowel syndrome with constipation and the company plans to file a new drug application supplement with clinical data (sNDA) in the first quarter of 2017. Dolcanatide is being explored for ulcerative colitis.